School of Pharmacy, Institute of Aging Medicine, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai 264003, PR China.
School of Pharmacy, Institute of Aging Medicine, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai 264003, PR China.
J Control Release. 2024 Dec;376:794-805. doi: 10.1016/j.jconrel.2024.10.049. Epub 2024 Nov 1.
Radiotherapy (RT)-mediated immune activation is insufficient for effective therapy of triple-negative breast cancer (TNBC) due to the immunosuppressive tumor microenvironment. Herein, we developed an oxygen self-supplying nanoradiosensitizer to activate immunogenic cell death (ICD) and the cGAS-STING signaling pathway, elevating the anti-tumor immune response and improving radioimmunotherapy for TNBC. The nanoradiosensitizer was fabricated using astragaloside liposome-encapsulated FePt alloy and MnO nanocrystals (ALFM). The ALFM targeted the glucose transporter-1 (GLUT-1) receptor in TNBC and effectively entered tumor cells. Subsequently, the ALFM responded to the weakly acidic tumor microenvironment and degraded, releasing FePt and Mn ions. The released Mn ions not only elevated cellular ROS levels via a Fenton-like reaction but also activated the cGAS-STING signaling pathway, which stimulated the anti-tumor immune response. In addition, the FePt alloy catalyzed a cascade reaction, producing ROS and O in tumor cells, alleviating tumor hypoxia, and enhancing the RT effect. Besides, ROS-mediated cell damage induced the ICD effect in TNBC, promoted dendritic cell maturation and the infiltration of cytotoxic T lymphocytes, ultimately eliciting cancer immunotherapy. In vivo experimental results demonstrated that ALFM effectively activated the antitumor immune response and improved the radioimmunotherapy effect for TNBC. Overall, this work presents an effective strategy for enhanced radioimmunotherapy of TNBC.
放射治疗(RT)介导的免疫激活不足以有效治疗三阴性乳腺癌(TNBC),因为肿瘤微环境具有免疫抑制性。在此,我们开发了一种氧自供纳米放射增敏剂,以激活免疫原性细胞死亡(ICD)和 cGAS-STING 信号通路,提高抗肿瘤免疫反应,改善 TNBC 的放免治疗。该纳米放射增敏剂由黄芪脂体包封的 FePt 合金和 MnO 纳米晶体(ALFM)制成。ALFM 靶向 TNBC 中的葡萄糖转运蛋白-1(GLUT-1)受体,并有效进入肿瘤细胞。随后,ALFM 响应弱酸性肿瘤微环境并降解,释放出 FePt 和 Mn 离子。释放的 Mn 离子不仅通过芬顿样反应提高了细胞内 ROS 水平,还激活了 cGAS-STING 信号通路,刺激了抗肿瘤免疫反应。此外,FePt 合金催化级联反应,在肿瘤细胞中产生 ROS 和 O,减轻肿瘤缺氧,并增强 RT 效果。此外,ROS 介导的细胞损伤在 TNBC 中诱导 ICD 效应,促进树突状细胞成熟和细胞毒性 T 淋巴细胞浸润,最终引发癌症免疫治疗。体内实验结果表明,ALFM 有效激活了抗肿瘤免疫反应,提高了 TNBC 的放免治疗效果。总的来说,这项工作提出了一种增强 TNBC 放免治疗的有效策略。